## Protocol Section
### Identification Module
**NCT ID:** NCT06422884

**Brief Title:** A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

**Official Title:** A Phase 2, Multi-Center, Randomized, Double-Blind, Controlled Trial Evaluating the Safety and Efficacy of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

#### Organization Study ID Info
**ID:** ENV-IPF-103
#### Organization
**Class:** INDUSTRY
**Full Name:** Endeavor Biomedicines, Inc.
### Status Module
#### Completion Date
**Date:** 2026-06

**Type:** ESTIMATED

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2024-05-21

**Type:** ACTUAL

**Last Update Submit Date:** 2024-05-15

**Overall Status:** NOT_YET_RECRUITING

#### Primary Completion Date
**Date:** 2026-06

**Type:** ESTIMATED

#### Start Date
**Date:** 2024-09

**Type:** ESTIMATED

**Status Verified Date:** 2024-05

#### Study First Post Date
**Date:** 2024-05-21
**Type:** ACTUAL
**Study First Submit Date:** 2024-05-15
**Study First Submit QC Date:** 2024-05-15
### Sponsor Collaborators Module

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Endeavor Biomedicines, Inc.

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Is FDA Regulated Device:** False

**Is FDA Regulated Drug:** True

**Is US Export:** True

**Oversight Has DMC:** True

### Description Module

**Brief Summary:** The goal of this clinical trial is to evaluate the impact that ENV-101 has on lung function and key measures of fibrosis in adult patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Another goal of this study is to better understand the safety and tolerability of ENV-101 in these patient populations.

**Detailed Description:** This trial is a 6-month, randomized, double-blind, controlled, dose-ranging trial of ENV-101 in two parallel cohorts of adult patients with lung fibrosis: idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF). Patients are allowed to continue treatment with approved standard of care (e.g., nintedanib, pirfenidone) during the trial. Patients will be randomized to one of 3 dose levels of ENV-101 or placebo at baseline. The objectives of this trial are to characterize the efficacy, antifibrotic activity, and safety of ENV-101 to select the Phase 3 dose of ENV-101 in each indication.

### Conditions Module

**Conditions:**

- Idiopathic Pulmonary Fibrosis

- Progressive Pulmonary Fibrosis

- Progressive Fibrosing Interstitial Lung Disease

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** TRIPLE

**Who Masked:**

- PARTICIPANT

- INVESTIGATOR

- OUTCOMES_ASSESSOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 320

**Type:** ESTIMATED

**Phases:**

- PHASE2

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 Low Dose (IPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 2

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 Mid Dose (IPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 3

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 High Dose (IPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 4

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo (IPF Population)

**Type:** PLACEBO_COMPARATOR

#### Arm Group 5

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 Low Dose (PPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 6

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 Mid Dose (PPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 7

**Intervention Names:**

- Drug: ENV-101

**Label:** ENV-101 High Dose (PPF Population)

**Type:** EXPERIMENTAL

#### Arm Group 8

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo (PPF Population)

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- ENV-101 High Dose (IPF Population)

- ENV-101 High Dose (PPF Population)

- ENV-101 Low Dose (IPF Population)

- ENV-101 Low Dose (PPF Population)

- ENV-101 Mid Dose (IPF Population)

- ENV-101 Mid Dose (PPF Population)

**Description:** oral tablet, dosed once a day

**Name:** ENV-101

**Other Names:**

- taladegib

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Placebo (IPF Population)

- Placebo (PPF Population)

**Description:** oral tablet, dosed once a day

**Name:** Placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Description:** ppFVC is a measure of lung function

**Measure:** IPF Population Primary Endpoint: Rate of change in percent predicted forced vital capacity (ppFVC) compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** The incidence, severity, and relationship of treatment-emergent adverse events (TEAEs), and treatment-emergent and clinically significant changes in lab parameters, vital signs, electrocardiogram (ECG), and oxygen saturation

**Measure:** PPF Population Primary Endpoint: Safety

**Time Frame:** Baseline and Week 24

#### Secondary Outcomes

**Measure:** PPF Population: Rate of change in ppFVC compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** FVC is a measure of lung function

**Measure:** Absolute change in FVC (mL) compared to placebo

**Time Frame:** Baseline and Week 24

**Measure:** Time to disease progression (absolute decline in ppFVC >10%, IPF-related hospitalization, or death) compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** The L-PF Symptoms Questionnaire Cough domain consists of 6 questions regarding a subject's experience with cough over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Cough domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

**Measure:** Absolute change in the Living with Pulmonary Fibrosis Symptoms (L-PF Symptoms) Questionnaire Cough domain score compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** The L-PF Symptoms Questionnaire Dyspnea domain consists of 12 questions regarding a subject's experience with dyspnea (shortness of breath) over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Dyspnea domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

**Measure:** Absolute change in the L-PF Symptoms Questionnaire Dyspnea domain score compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** The L-PF Symptoms Questionnaire Fatigue domain consists of 5 questions regarding a subject's experience with fatigue over the prior 24 hours. Questions have response options on a five-point numeric rating scale with an anchor of 0 ("Not at all") to 4 ("Extremely"). Total score for the Fatigue domain is normalized to the range 0 to 100, with higher scores indicating greater impairment.

**Measure:** Absolute change in the L-PF Symptoms Questionnaire Fatigue domain score compared to placebo

**Time Frame:** Baseline and Week 24

**Description:** HRCT is a method of imaging which is more precise than chest x-ray in the diagnosis and monitoring of diseases of the lung tissue and the airways.

**Measure:** Absolute change in total lung capacity (TLC) by chest high-resolution computed tomography (HRCT) imaging compared to placebo

**Time Frame:** Baseline and Week 24

**Measure:** Absolute change in % quantitative interstitial lung disease (QILD) by chest HRCT imaging compared to placebo compared to placebo

**Time Frame:** Baseline and Week 24

**Measure:** Absolute change in % quantitative ground glass opacity (QGG) by chest HRCT imaging compared to placebo

**Time Frame:** Baseline and Week 24

**Measure:** Absolute change in % quantitative lung fibrosis (QLF) by chest HRCT imaging compared to placebo

**Time Frame:** Baseline and Week 24

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* IPF Population: Patients ≥ 40 years old with an IPF diagnosis as confirmed by the Investigator.
* PPF Population: Patients ≥ 18 years old (or the minimum legal adult age, whichever is greater) with a diagnosis of PPF, as confirmed by the Investigator.
* Percent predicted FVC of ≥ 45% at study start.
* Percent predicted diffusing capacity of lung for carbon monoxide (DLCO) ≥ 25%, adjusted for hemoglobin (Hgb) at study start.
* Ability to perform spirometry tests.
* Either stable treatment with standard of care (SoC) \[i.e., antifibrotics, immunosuppressants (PPF only)\] for at least 3 months prior to study start or not treated with SoC for at least 8 weeks prior to study start.

Exclusion Criteria:

* IPF Population: Evidence of other known causes of interstitial lung disease (ILD)
* Forced expiratory volume in one second (FEV1)/FVC ratio \<0.7 at study start.
* History of malignancy, including carcinoma during the preceding 5 years from study start, with the following exceptions:

  1. Prior history of in situ melanoma, basal or squamous cell skin cancer if treated with curative therapy.
  2. Patients with prostate cancer that are managed by surveillance.
  3. Patients with ductal carcinoma in situ, treated surgically with curative intent.
* Patients with moderate to severe hepatic impairment (Child-Pugh B and C).
* Smoking (including vaping) within 6 months of study start; current smoker, or unwillingness to refrain from smoking during the clinical trial duration.
* Active or suspected alcohol or drug abuse in the opinion of the Investigator.
* Currently enrolled in another investigational device or drug trial, or less than 3 months from study start since ending another investigational device or drug trial(s) or receiving other investigational treatment(s).
* Presence of active infection at study start or confirmed active human immunodeficiency virus (HIV), Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
* Major surgery requiring hospitalization (according to the Investigator) performed within 3 months prior to study start or planned during the course of the trial. Being on a transplant list is allowed.
* Occurrence of serious illness requiring hospitalization within 90 days prior to study start.
* Current or previous use (within 28 days prior to study start) of the following:

  1. Endothelin receptor antagonist
  2. Riociguat
  3. Prostacyclin or prostacyclin analogue
  4. Radiation to the lungs
  5. Oral corticosteroids \>15 mg/day
* Use of cyclophosphamide or tocilizumab within 8 weeks, or rituximab within 6 months, prior to study start.
* Use of drugs that are known moderate or stronger CYP3A4 inhibitors or inducers within 14 days prior to study start. Patients must also agree not to eat fruits that inhibit CYP3A4 such as grapefruit, Seville oranges, pomelo and star fruit.
* Patients of reproductive potential who are sexually active and unwilling to use birth control for the duration of the study and for 3 months after their final dose of study drug.
* Females that are pregnant or nursing.
* Patients that are unwilling to refrain from blood or blood product donation for the duration of the study and for 30 days after their final dose of study drug.
* Males who are unwilling to refrain from sperm donation and females who are unwilling to refrain from egg donation for the duration of the study and for 3 months after their final dose of study drug.
* Patients with a history of a severe allergic reaction or anaphylactic reaction or known hypersensitivity to any component of ENV-101.
* Patients who have previously taken ENV-101.

**Sex:** ALL

**Standard Ages:**

- CHILD

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Central Contacts

**Contact 1:**

**Email:** ebmclinical@endeavorbiomedicines.com

**Name:** Endeavor Clinical Trials

**Phone:** 1-858-727-3199

**Role:** CONTACT

#### Locations

**Location 1:**

**City:** Birmingham

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Alabama

**Zip:** 35233

**Location 2:**

**City:** Phoenix

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Arizona

**Zip:** 85013

**Location 3:**

**City:** Gainesville

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Florida

**Zip:** 32608

**Location 4:**

**City:** Maywood

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Illinois

**Zip:** 60153

**Location 5:**

**City:** Kansas City

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Kansas

**Zip:** 66160

**Location 6:**

**City:** Ann Arbor

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Michigan

**Zip:** 48109

**Location 7:**

**City:** Royal Oak

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Michigan

**Zip:** 48073

**Location 8:**

**City:** Portland

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Studies

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Oregon

**Zip:** 97220

**Location 9:**

**City:** Philadelphia

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Pennsylvania

**Zip:** 19107

**Location 10:**

**City:** Philadelphia

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Pennsylvania

**Zip:** 19140

**Location 11:**

**City:** Dallas

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Zip:** 75246

**Location 12:**

**City:** San Antonio

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 858-727-3199

- **Role:** CONTACT

**Country:** United States

**Facility:** Research Site

**State:** Texas

**Zip:** 78229

**Location 13:**

**City:** South Brisbane

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Australia

**Facility:** Research Site

**State:** Queensland

**Zip:** 4101

**Location 14:**

**City:** Adelaide

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Australia

**Facility:** Research Site

**State:** South Australia

**Zip:** 5000

**Location 15:**

**City:** Box Hill

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Australia

**Facility:** Research Site

**State:** Victoria

**Zip:** 3128

**Location 16:**

**City:** Melbourne

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Australia

**Facility:** Research Site

**State:** Victoria

**Zip:** 3004

**Location 17:**

**City:** Nedlands

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Australia

**Facility:** Research Site

**State:** Western Australia

**Zip:** 6009

**Location 18:**

**City:** Vienna

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Austria

**Facility:** Research Site

**Zip:** 1090

**Location 19:**

**City:** Vancouver

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Canada

**Facility:** Research Site

**State:** British Columbia

**Zip:** V6Z 2K5

**Location 20:**

**City:** Sherbrooke

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Canada

**Facility:** Research Site

**State:** Quebec

**Zip:** J1H 5N4

**Location 21:**

**City:** Munich

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Germany

**Facility:** Research Site

**Zip:** 81377

**Location 22:**

**City:** Dublin

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Ireland

**Facility:** Research Site

**Zip:** D04 T6F4

**Location 23:**

**City:** Ulsan

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Dong District)

**Zip:** 44033

**Location 24:**

**City:** Seoul

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Gangnam District)

**Zip:** 135-710

**Location 25:**

**City:** Busan

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Haeundae District)

**Location 26:**

**City:** Seoul

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Seongbuk District)

**Zip:** 02841

**Location 27:**

**City:** Seoul

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Songpa District)

**Zip:** 05505

**Location 28:**

**City:** Seoul

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Korea, Republic of

**Facility:** Research Site

**State:** (Yongsan District)

**Zip:** 04401

**Location 29:**

**City:** Kuala Lumpur

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Malaysia

**Facility:** Research Site

**Zip:** 50590

**Location 30:**

**City:** Selayang Baru Utara

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Malaysia

**Facility:** Research Site

**Location 31:**

**City:** Monterrey

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**State:** Nuevo Leon

**Zip:** 64060

**Location 32:**

**City:** Monterrey

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**State:** Nuevo Leon

**Zip:** 64718

**Location 33:**

**City:** San Nicolás De Los Garza

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**State:** Nuevo Leon

**Zip:** 66465

**Location 34:**

**City:** San Juan Del Río

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**State:** Queretaro

**Zip:** 76800

**Location 35:**

**City:** Chihuahua

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**Zip:** 31203

**Location 36:**

**City:** Mexico City

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**Zip:** 14080

**Location 37:**

**City:** Oaxaca

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**Zip:** 68000

**Location 38:**

**City:** Puebla

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Mexico

**Facility:** Research Site

**Zip:** 72180

**Location 39:**

**City:** Bern

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** Switzerland

**Facility:** Research Site

**Zip:** 3010

**Location 40:**

**City:** Edinburgh

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** United Kingdom

**Facility:** Research Site

**Zip:** EH1 3EG

**Location 41:**

**City:** Exeter

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** United Kingdom

**Facility:** Research Site

**Zip:** EX2 5DW

**Location 42:**

**City:** London

**Contacts:**

***Contact 1:***

- **Email:** ebmclinical@endeavorbiomedicines.com

- **Name:** Endeavor Clinical Trials

- **Phone:** 1-858-727-3199

- **Role:** CONTACT

**Country:** United Kingdom

**Facility:** Research Site

**Zip:** SW3 6NP

#### Overall Officials

**Official 1:**

**Affiliation:** Endeavor Biomedicines

**Name:** Paul Frohna, M.D., Ph.D., Pharm.D.

**Role:** STUDY_DIRECTOR

### IPD Sharing Statement Module

**IPD Sharing:** NO

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000010335

- Term: Pathologic Processes

- ID: D000012140

- Term: Respiratory Tract Diseases

### Condition Browse Module - Browse Branches

- Abbrev: BC08

- Name: Respiratory Tract (Lung and Bronchial) Diseases

- Abbrev: All

- Name: All Conditions

- Abbrev: BC23

- Name: Symptoms and General Pathology

- Abbrev: Rare

- Name: Rare Diseases

### Condition Browse Module - Browse Leaves

- ID: M11168

- Name: Lung Diseases

- Relevance: HIGH

- As Found: Lung Disease

- ID: M8485

- Name: Fibrosis

- Relevance: HIGH

- As Found: Fibrosis

- ID: M14512

- Name: Pulmonary Fibrosis

- Relevance: HIGH

- As Found: Pulmonary Fibrosis

- ID: M27989

- Name: Idiopathic Pulmonary Fibrosis

- Relevance: HIGH

- As Found: Idiopathic Pulmonary Fibrosis

- ID: M19813

- Name: Lung Diseases, Interstitial

- Relevance: HIGH

- As Found: Interstitial Lung Disease

- ID: M14977

- Name: Respiratory Tract Diseases

- Relevance: LOW

- As Found: Unknown

- ID: T3003

- Name: Idiopathic Pulmonary Fibrosis

- Relevance: HIGH

- As Found: Idiopathic Pulmonary Fibrosis

### Condition Browse Module - Meshes

- ID: D000008171

- Term: Lung Diseases

- ID: D000011658

- Term: Pulmonary Fibrosis

- ID: D000054990

- Term: Idiopathic Pulmonary Fibrosis

- ID: D000017563

- Term: Lung Diseases, Interstitial

- ID: D000005355

- Term: Fibrosis

### Misc Info Module

- Version Holder: 2024-05-31
